— US revenue rose 8% to $185.6 million, while overseas revenue moved up 29% to $36 million
— Third-quarter gross margin was 82%, down from 83% reported a year earlier
— Announced initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading Pivotal Randomized Controlled Trial during the quarter
ADVERTISEMENT
— Expects full-year 2020 revenue to be in the range of $846 million to $877 million, up 10% to 14% respectively
— Confirms full-year 2020 unadjusted operating margin guidance in the range of 28% to 30%